PTC Therapeutics (PTCT) Competitors

Genmab A/S (NASDAQ:GMAB) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Which has more risk and volatility, GMAB or PTCT?

Genmab A/S has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Does the media refer more to GMAB or PTCT?

In the previous week, PTC Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for PTC Therapeutics and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.00 beat PTC Therapeutics' score of 0.64 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in GMAB or PTCT?

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has preferable earnings & valuation, GMAB or PTCT?

Genmab A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.81	$1.14B	$1.99	11.77
PTC Therapeutics	$806.78M	4.90	-$363.30M	$6.97	7.14

Is GMAB or PTCT more profitable?

Genmab A/S has a net margin of 37.53% compared to PTC Therapeutics' net margin of 35.65%. Genmab A/S's return on equity of 21.03% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
PTC Therapeutics	35.65%	-106.31%	30.61%

Do analysts prefer GMAB or PTCT?

Genmab A/S currently has a consensus target price of $37.60, suggesting a potential upside of 60.55%. PTC Therapeutics has a consensus target price of $70.15, suggesting a potential upside of 40.87%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
PTC Therapeutics	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Genmab A/S beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.